Insulet | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Abbott USD 6.03B 93M 2024-12
Align Technology USD 696.94M 15.17M 2024-12
AtriCure USD 92.62M 5.83M 2024-12
Avanos Medical USD 98M 5.1M 2024-12
Baxter International USD 1.02B 19M 2024-12
Becton, Dickinson and Co. USD 2.24B 290M 2024-12
Boston Scientific USD 3.1B 194M 2024-12
Cardinal Health USD 1.94B 39M 2024-12
Cooper Companies USD 660.2M 17.5M 2025-01
Dexcom USD 709.3M 115.5M 2024-12
Edwards Lifesciences USD 1.09B 2.1M 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Globus Medical USD 393.86M 38.67M 2024-12
ICU Medical USD 227.26M 22.41M 2024-12
Insulet USD 430.9M 53.8M 2024-12
Integra LifeSciences USD 265.84M 47.8M 2024-12
J&J USD 15.41B 102M 2024-12
Masimo USD 244.7M 18.5M 2024-12
Medtronic USD 5.52B 49M 2025-01
Merit Medical Systems USD 172.98M 15.45M 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Solventum Corp 1.12B 46M 2024-12
Stryker USD 4.2B 681M 2024-12
Tandem Diabetes Care USD 157.45M 32.8M 2024-12
Teleflex USD 439.92M 9.74M 2024-12
West Pharmaceutical Services USD 273.6M 8.9M 2024-12
Zimmer Biomet Holdings USD 1.44B 150.9M 2024-12



Insulet Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.